Navigation Links
NUS researchers make new discovery of protein as a promising target for treatment of ATC
Date:2/18/2014

Anaplastic thyroid carcinoma (ATC) is an aggressive type of cancer with a poor prognosis for which there is currently no effective treatment. Researchers from the National University of Singapore (NUS) have discovered for the first time that an epithelial basement membrane protein, called laminin-5 gamma-2 (LAMC2), has the potential to be an ideal target for the treatment of ATC.

Led by Professor H. Phillip Koeffler, Senior Principal Investigator, and Dr Manoj Garg, Research Fellow, at the Cancer Science Institute of Singapore (CSI Singapore) at NUS, the team is also the first to demonstrate that effect of LAMC2 on cell growth, cell cycle, migration and invasion in ATC cells. This novel study was published in the Journal of Clinical Endocrinology and Metabolism last month.

Thyroid cancer is the most common cancer of the endocrine system. ATC are undifferentiated tumours of the thyroid follicular epithelium. This type of cancer has a poor prognosis due to their extremely aggressive nature and resistance to treatment. Overall survival from diagnosis is typically six months or less. As such, new therapeutic targets are needed to improve the clinical care of these patients.

The effect of LAMC2 on ATC cells

In their study, the researchers found that LAMC2 is over-expressed in a large cohort of ATC patient samples. Analysis of RNA data of ATC cells showed that LAMC2 is likely to play a role in the formation of tumours. They discovered that silencing of LAMC2 in ATC cells reduced their cell growth, migration and invasion. In addition, silencing of this protein impaired the cell cycle of ATC cells by arresting them at the growth phase to DNA replication phase, or the G1 to S phase transition, of their cell cycle.

At the same time, the study found that LAMC2 enhanced activation of growth signals through a cell surface protein called epidermal growth factor receptor (EGFR) in ATC cells. EGFR plays an important role in the behaviour of malignant cells in a variety of human tumours by increasing proliferation. Increased expression of epidermal growth factor and EGFR has been detected in 58 per cent to 87 per cent of ATC when compared with normal tissue. The researchers demonstrated that simultaneous silencing of LAMC2 combined with various ways of silencing EGFR effectively inhibited the growth of tumour cells.

The novel study provides a foundation for further investigation of LAMC2 as a promising target for developing novel therapeutic approaches for the treatment of ATC.

Said Prof Koeffler, "Our findings provide a novel target for therapeutic research. We are now extending these investigations to additional types of frequent cancer subtypes."


'/>"/>

Contact: Kimberley Wang
kimberley.wang@nus.edu.sg
National University of Singapore
Source:Eurekalert

Related medicine news :

1. Scripps researchers recommend mobile compression device to prevent DVT after joint surgery
2. No such thing as porn addiction, researchers say
3. LA BioMed researchers report on promising new therapy for devastating genetic disorder
4. NIH-funded researchers use antibody treatment to protect humanized mice from HIV
5. Researchers blend orthopedics, engineering to better repair torn rotator cuffs
6. Researchers discover new hormone receptors to target when treating breast cancer
7. Kessler Foundation MS researchers study predictors of employment status
8. RI Hospital researchers identify components in C. diff that may lead to better treatment
9. Researchers create database to examine vast resources of health legacy foundations
10. UC Irvine stem cell researchers awarded $1.54 million in state funding
11. Researchers find novel approach for controlling deadly C. difficile infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical ... Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. ... honor of Morris F. Collen, a pioneer in the field of medical informatics, this ...
(Date:10/12/2017)... ... 12, 2017 , ... Dr. Parsa Mohebi, the Los Angeles ... to the newly revamped Cosmetic Town journal section, featuring articles written ... known as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I ...
(Date:10/12/2017)... ... , ... On Saturday, October 21, the Health & Wellness Center at Florida ... money for the American Heart Association Heart Walk. Teams of up to 10 people ... keep their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the ... a year. In some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, ... retirement havens have extremely low property-tax rates, which contributes to the relatively lower ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vodori, Inc., ... promotional review platform at the Promotional Review Committee Compliance and Best Practices ... streamline the medical, legal, and regulatory review (MLR) process – which ensures ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... DIEGO , Sept. 22, 2017 AVACEN ... medical device is now successfully helping those with the ... Fibromyalgia diagnosed Amanda in Essex, ... dressed and washing my hair, experiencing no sleep at ... in painful spasm… I cannot recommend [the AVACEN 100] ...
(Date:9/18/2017)... Sept. 18, 2017 EpiVax, Inc. ... bioinformatics and immune engineering, today announced a ... A (H7N9) vaccine. ... seasonal influenza and presents a challenge for ... exposure to be effective. Using state-of-the-art bioinformatics and ...
(Date:9/12/2017)... Sept. 12, 2017  ValGenesis Inc., the global ... is pleased to announce the appointment of Dr. ... its Board of Directors and Chairman of Advisory ... life science companies to manage their entire validation ... paper in this process. Furthermore, ValGenesis VLMS enables ...
Breaking Medicine Technology: